Embree Financial Group Acquires 5,528 Shares of Abbott Laboratories $ABT

Embree Financial Group grew its holdings in shares of Abbott Laboratories (NYSE:ABT) by 22.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 30,659 shares of the healthcare product maker’s stock after buying an additional 5,528 shares during the period. Embree Financial Group’s holdings in Abbott Laboratories were worth $3,841,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Cloud Capital Management LLC bought a new position in Abbott Laboratories during the third quarter worth $29,000. Guerra Advisors Inc bought a new stake in Abbott Laboratories in the third quarter valued at $31,000. Delos Wealth Advisors LLC acquired a new position in shares of Abbott Laboratories during the second quarter valued at about $32,000. Bridge Generations Wealth Management LLC bought a new position in shares of Abbott Laboratories during the 3rd quarter worth about $33,000. Finally, Copia Wealth Management acquired a new stake in shares of Abbott Laboratories in the 3rd quarter valued at about $38,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on ABT shares. Leerink Partners dropped their price target on Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating on the stock in a research note on Friday, January 30th. Barclays reduced their price objective on Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating for the company in a research note on Monday, February 2nd. Raymond James Financial lowered their target price on Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Daiwa Securities Group cut their target price on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating on the stock in a report on Friday, January 30th. Finally, Citigroup reduced their price target on shares of Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating for the company in a research report on Wednesday, March 11th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $136.16.

Abbott Laboratories Price Performance

ABT stock opened at $104.12 on Monday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58. The business has a 50-day simple moving average of $110.82 and a two-hundred day simple moving average of $122.01. The company has a market capitalization of $181.35 billion, a P/E ratio of 27.99, a price-to-earnings-growth ratio of 1.65 and a beta of 0.74. Abbott Laboratories has a 52-week low of $102.41 and a 52-week high of $139.06.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting the consensus estimate of $1.50. The firm had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The company’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period in the prior year, the business posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Research analysts expect that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 annualized dividend and a yield of 2.4%. Abbott Laboratories’s dividend payout ratio (DPR) is 67.74%.

Insider Activity

In other Abbott Laboratories news, SVP Eric Shroff sold 709 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $81,946.22. Following the transaction, the senior vice president owned 39,164 shares of the company’s stock, valued at $4,526,575.12. This trade represents a 1.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $102,288.30. Following the completion of the transaction, the executive vice president owned 146,377 shares in the company, valued at $16,918,253.66. The trade was a 0.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 3,055 shares of company stock worth $353,097. Company insiders own 0.46% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.